MARKETS

BSE Prices delayed by 5 minutes... Prices as on Feb 22, 2019   ABB India 1248.85 [ -0.07% ]ACC 1384.7 [ -0.39% ]Ambuja Cements Ltd. 211.25 [ 0.60% ]Asian Paints Ltd. 1398.3 [ 0.04% ]Axis Bank Ltd. 703.05 [ 0.88% ]Bajaj Auto Ltd. 2816.7 [ 0.25% ]Bank of Baroda 102.85 [ -0.15% ]Bharti Airtel 313 [ 0.90% ]Bharat Heavy Ele 63.6 [ 1.19% ]Bharat Petroleum 344.85 [ 2.94% ]Britannia Ind. 3014.3 [ 0.33% ]Cairn India Ltd. 285.4 [ 0.90% ]Cipla 541.75 [ -0.25% ]Coal India 215.25 [ 0.73% ]Colgate Palm. 1255.45 [ 1.30% ]Dabur India 434.2 [ 1.77% ]DLF Ltd. 169.3 [ 2.17% ]Dr. Reddy's Labs 2637.4 [ 2.01% ]GAIL (India) Ltd. 327.3 [ -1.34% ]Grasim Inds. 758.3 [ 1.57% ]HCL Technologies 1063.15 [ 0.92% ]HDFC 1885.05 [ -0.35% ]HDFC Bank 2091.65 [ -1.11% ]Hero MotoCorp 2687.35 [ 1.65% ]Hindustan Unilever L 1767.8 [ 0.81% ]Hindalco Indus. 196.6 [ 1.18% ]ICICI Bank 351.75 [ 0.39% ]IDFC L 37.1 [ 2.63% ]Indian Hotels Co 142.65 [ -0.31% ]IndusInd Bank 1463.35 [ -0.56% ]Infosys 733.35 [ 0.00% ]ITC Ltd. 274.3 [ -0.22% ]Jindal St & Pwr 159.1 [ 2.41% ]Kotak Mahindra Bank 1241.05 [ -3.71% ]L&T 1279.45 [ -0.22% ]Lupin Ltd. 776.85 [ 0.88% ]Mahi. & Mahi 646.1 [ 2.01% ]Maruti Suzuki India 6916.4 [ 1.76% ]MTNL 13.39 [ -3.60% ]Nestle India 10687.3 [ 0.85% ]NIIT Ltd. 81.85 [ -1.03% ]NMDC Ltd. 96.7 [ 1.47% ]NTPC 139.7 [ 2.27% ]ONGC 148.55 [ 1.05% ]Punj. NationlBak 73.2 [ 0.00% ]Power Grid Corpo 181.9 [ 0.08% ]Reliance Inds. 1232.6 [ -1.11% ]SBI 270.75 [ 1.20% ]Vedanta 169.3 [ 2.86% ]Shipping Corpn. 36.25 [ 2.40% ]Sun Pharma. 430.4 [ 0.15% ]Tata Chemicals 566.35 [ -0.05% ]Tata Global Beverage 189.75 [ -0.11% ]Tata Motors Ltd. 174.55 [ 2.86% ]Tata Steel 501.95 [ 0.81% ]Tata Power Co. 67.1 [ -0.45% ]Tata Consultancy 1925.9 [ 0.71% ]Tech Mahindra Ltd. 825.2 [ 0.59% ]UltraTech Cement 3621.05 [ -0.28% ]United Spirits 533.1 [ -0.48% ]Wipro Ltd 379 [ 1.20% ]Zee Entertainment En 448.6 [ 0.46% ]

News Details

You can view in detail.
Cipla targets $1-bn revenues from domestic market in FY19 11/06/2018 00:46

Country's fourth-largest drug maker Cipla is bullish on growth and is looking for a billion dollar consolidated revenue for the domestic market in FY19, a senior company official said as per the PTI report.

The company reported revenues of Rs 15,219 crore, growing 6 per cent, with income from the India operations seeing a 6.3 per cent jump at Rs 5,687 crore in FY18.

"In terms of the domestic business we are on a strong footing as growth was in healthy double digits," Cipla global CFO Kedar Upadhye said at an earnings conference here.

"We are quite confident and we are set for a billion dollar consolidated revenue in the domestic market in FY19," Upadhye added.

The drug maker expects the in-licensing deals with innovator companies, focus on certain therapeutic segments and sales force productivity optimisation measures to aid growth in India.

"This financial year, our focus remained on strengthening our portfolio and deepening our presence in priority markets. We are happy that our efforts on cost and efficiency improvement helped us deliver the full year margin ahead of our guidance range," Cipla managing director and global CEO Umang Vohra said.

The focus for next year will be to continue on the growth trajectory in key markets, he added.

Commenting on inorganic growth plans, Vohra said, "We have taken an enabling resolution, does not mean that we will be doing deals worth Rs 4,000 crore. As and when they become available, we will be hopeful (of acquisition), but we will not buy unless we see a synergy value in the transaction."

Last year the company had taken an enabling resolution to raise funds of about Rs 2,000 crore of debt and Rs 2,000 crore of equity.

The company is also looking at consolidating its position in South Africa, US, Europe and emerging markets.

"We will ramp up our US business, which is poised for good growth during this year with our key differentiated launches," Vohra said.

The company is also looking at significant investments in R&D to build a strong pipeline, with over 20 targeted filings in FY19. This year will also see higher investments towards clinical trials for key respiratory assets and focus on building specialty assets, Vohra added.

LOAD MORE